Benign metastasizing giant cell tumors of bone. A DNA flow cytometric study

Cancer. 1989 Oct 1;64(7):1521-6. doi: 10.1002/1097-0142(19891001)64:7<1521::aid-cncr2820640727>3.0.co;2-7.

Abstract

Approximately 2% of histologically benign giant cell tumors (BGCT) of bone are complicated by lung metastases, which can progress despite their benign histologic appearance. Almost all BGCT studied by DNA flow cytometry (FCM) have been reported to be diploid. However, the very few cases with lung metastases previously analyzed were all aneuploid. To assess the usefulness of DNA FCM in predicting the metastatic potential of BGCT, seven metastasizing BGCT were studied by DNA FCM using paraffin-embedded tissue. Five were purely diploid, one was tetraploid, and one was aneuploid. The primary and the metastasis showed the same DNA distribution in all but the tetraploid case, in which the metastasis was purely diploid. A single patient, who was in the diploid group, had unresectable tumor in the lungs; she remains alive with stable disease at 30 months. The other six patients, who underwent complete resections of their lung metastases, are free of disease. These results suggest that DNA FCM is not a sensitive method for predicting the metastatic potential of BGCT since most metastasizing cases appear to be diploid.

MeSH terms

  • Aneuploidy
  • Bone Neoplasms / genetics
  • Bone Neoplasms / pathology*
  • DNA, Neoplasm / analysis*
  • Flow Cytometry
  • Giant Cell Tumors / genetics
  • Giant Cell Tumors / pathology*
  • Giant Cell Tumors / secondary
  • Humans
  • Lung Neoplasms / secondary*

Substances

  • DNA, Neoplasm